BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

210 related articles for article (PubMed ID: 20970379)

  • 1. How important is whole brain radiotherapy for treatment of primary CNS lymphoma?
    Cabanillas F
    Lancet Oncol; 2010 Nov; 11(11):1011-2. PubMed ID: 20970379
    [No Abstract]   [Full Text] [Related]  

  • 2. High-dose methotrexate with or without whole brain radiotherapy for primary CNS lymphoma (G-PCNSL-SG-1): a phase 3, randomised, non-inferiority trial.
    Thiel E; Korfel A; Martus P; Kanz L; Griesinger F; Rauch M; Röth A; Hertenstein B; von Toll T; Hundsberger T; Mergenthaler HG; Leithäuser M; Birnbaum T; Fischer L; Jahnke K; Herrlinger U; Plasswilm L; Nägele T; Pietsch T; Bamberg M; Weller M
    Lancet Oncol; 2010 Nov; 11(11):1036-47. PubMed ID: 20970380
    [TBL] [Abstract][Full Text] [Related]  

  • 3. High-dose chemotherapy with autologous stem-cell transplantation and hyperfractionated radiotherapy as first-line treatment of primary CNS lymphoma.
    Illerhaus G; Marks R; Ihorst G; Guttenberger R; Ostertag C; Derigs G; Frickhofen N; Feuerhake F; Volk B; Finke J
    J Clin Oncol; 2006 Aug; 24(24):3865-70. PubMed ID: 16864853
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Preliminary results of combined chemotherapy and radiotherapy for non-AIDS primary central nervous system lymphoma. Trans-Tasman Radiation Oncology Group (TROG).
    O'Brien PC; Roos DE; Liew KH; Trotter GE; Barton MB; Walker QJ; Poulsen MG; Olver IN
    Med J Aust; 1996 Oct; 165(8):424-7. PubMed ID: 8913243
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Importance of radiotherapy in the outcome of patients with primary CNS lymphoma: an analysis of the CHOD/BVAM regimen followed by two different radiotherapy treatments.
    Bessell EM; López-Guillermo A; Villá S; Verger E; Nomdedeu B; Petit J; Byrne P; Montserrat E; Graus F
    J Clin Oncol; 2002 Jan; 20(1):231-6. PubMed ID: 11773174
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Results of treatment of 112 cases of primary CNS lymphoma.
    Yamanaka R; Morii K; Shinbo Y; Homma J; Sano M; Tsuchiya N; Yajima N; Tamura T; Hondoh H; Takahashi H; Kakuma T; Tanaka R
    Jpn J Clin Oncol; 2008 May; 38(5):373-80. PubMed ID: 18413337
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Analysis of radiotherapy in 1054 patients with primary central nervous system lymphoma treated from 1985 to 2009.
    Shibamoto Y; Sumi M; Takemoto M; Tsuchida E; Onodera S; Matsushita H; Sugie C; Tamaki Y; Onishi H
    Clin Oncol (R Coll Radiol); 2014 Oct; 26(10):653-60. PubMed ID: 25034088
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Primary central nervous system lymphoma: Phase I evaluation of infusional bromodeoxyuridine with whole brain accelerated fractionation radiation therapy after chemotherapy.
    Dabaja BS; McLaughlin P; Ha CS; Pro B; Meyers CA; Seabrooke LF; Wilder RB; Kyritsis AP; Preti HA; Yung WK; Levin V; Cabanillas F; Cox JD
    Cancer; 2003 Sep; 98(5):1021-8. PubMed ID: 12942571
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Combined immunochemotherapy with reduced whole-brain radiotherapy for newly diagnosed primary CNS lymphoma.
    Shah GD; Yahalom J; Correa DD; Lai RK; Raizer JJ; Schiff D; LaRocca R; Grant B; DeAngelis LM; Abrey LE
    J Clin Oncol; 2007 Oct; 25(30):4730-5. PubMed ID: 17947720
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Randomized phase III study of whole-brain radiotherapy for primary CNS lymphoma.
    Korfel A; Thiel E; Martus P; Möhle R; Griesinger F; Rauch M; Röth A; Hertenstein B; Fischer T; Hundsberger T; Mergenthaler HG; Junghanß C; Birnbaum T; Fischer L; Jahnke K; Herrlinger U; Roth P; Bamberg M; Pietsch T; Weller M
    Neurology; 2015 Mar; 84(12):1242-8. PubMed ID: 25716362
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Primary non-Hodgkin's lymphoma of the CNS treated with CHOD/BVAM or BVAM chemotherapy before radiotherapy: long-term survival and prognostic factors.
    Bessell EM; Graus F; Lopez-Guillermo A; Lewis SA; Villa S; Verger E; Petit J
    Int J Radiat Oncol Biol Phys; 2004 Jun; 59(2):501-8. PubMed ID: 15145169
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Consolidation radiotherapy in primary central nervous system lymphomas: impact on outcome of different fields and doses in patients in complete remission after upfront chemotherapy.
    Ferreri AJ; Verona C; Politi LS; Chiara A; Perna L; Villa E; Reni M
    Int J Radiat Oncol Biol Phys; 2011 May; 80(1):169-75. PubMed ID: 20584577
    [TBL] [Abstract][Full Text] [Related]  

  • 13. High-dose chemotherapy and autologous stem-cell transplantation without consolidating radiotherapy as first-line treatment for primary lymphoma of the central nervous system.
    Illerhaus G; Müller F; Feuerhake F; Schäfer AO; Ostertag C; Finke J
    Haematologica; 2008 Jan; 93(1):147-8. PubMed ID: 18166803
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Combined treatment with high-dose methotrexate, vincristine and procarbazine, without intrathecal chemotherapy, followed by consolidation radiotherapy for primary central nervous system lymphoma in immunocompetent patients.
    Ferreri AJ; Reni M; Dell'Oro S; Ciceri F; Bernardi M; Camba L; Ponzoni M; Terreni MR; Tomirotti M; Spina M; Villa E
    Oncology; 2001; 60(2):134-40. PubMed ID: 11244328
    [TBL] [Abstract][Full Text] [Related]  

  • 15. MATILDE regimen followed by radiotherapy is an active strategy against primary CNS lymphomas.
    Ferreri AJ; Dell'Oro S; Foppoli M; Bernardi M; Brandes AA; Tosoni A; Montanari M; Balzarotti M; Spina M; Ilariucci F; Zaja F; Stelitano C; Bobbio F; Corazzelli G; Baldini L; Ponzoni M; Picozzi P; Caligaris Cappio F; Reni M
    Neurology; 2006 May; 66(9):1435-8. PubMed ID: 16682682
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Combined-modality therapy for primary central nervous system lymphoma: long-term data from a Phase II multicenter study (Trans-Tasman Radiation Oncology Group).
    O'Brien PC; Roos DE; Pratt G; Liew KH; Barton MB; Poulsen MG; Olver IN; Trotter GE;
    Int J Radiat Oncol Biol Phys; 2006 Feb; 64(2):408-13. PubMed ID: 16198065
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Response to chemotherapy and treating institution predict survival in primary central nervous system lymphoma.
    Korfel A; Martus P; Nowrousian MR; Hossfeld DK; Kirchen H; Brücher J; Stelljes M; Birkmann J; Peschel C; Pasold R; Fischer L; Jahnke K; Thiel E;
    Br J Haematol; 2005 Jan; 128(2):177-83. PubMed ID: 15638851
    [TBL] [Abstract][Full Text] [Related]  

  • 18. MATILDE chemotherapy regimen for primary CNS lymphoma: results at a median follow-up of 12 years.
    Ferreri AJ; Ciceri F; Brandes AA; Montanari M; Balzarotti M; Spina M; Ilariucci F; Zaja F; Stelitano C; Bobbio F; Corazzelli G; Baldini L; Reni M
    Neurology; 2014 Apr; 82(15):1370-3. PubMed ID: 24634458
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Primary CNS lymphoma: a clinician's guide.
    Schäfer N; Glas M; Herrlinger U
    Expert Rev Neurother; 2012 Oct; 12(10):1197-206. PubMed ID: 23082736
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Our experience with the treatment of primary lymphomas of the central nervous system].
    Motyčková M; Smolej L; Belada D; Malý J; Zák P
    Vnitr Lek; 2012 Dec; 58(12):915-21. PubMed ID: 23427949
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.